SCHEMBL522763

SCHEMBL522763

CN(Cc1ccccc1)CC1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.49
OPRM1 P35372 4/20 0.49
OPRD1 P41143 4/20 0.49
OPRK1 P41145 4/20 0.49
ALDH1A1 P00352 2/20 0.47
LMNA P02545 2/20 0.47
BLM P54132 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CARM1 Q86X55 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
PRMT8 Q9NR22 1/20 0.46
TSHR P16473 2/20 0.45
HRH3 Q9Y5N1 1/20 0.45
G6PC1 P35575 1/20 0.45
USP2 O75604 2/20 0.44
CYP3A4 P08684 1/20 0.44
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
PYCR1 P32322 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14045705 0.91 ALDH1A1 (0.52) SLC18A3OPRM1OPRD1OPRK1ALDH1A1
SCHEMBL8283980 0.84 ALDH1A1 (0.46) SLC18A3OPRM1OPRD1OPRK1ALDH1A1
SCHEMBL5651526 0.83 GBA1 (0.56) ALDH1A1LMNABLMSMN1; SMN2CARM1
SCHEMBL1191857 0.83 HTT (0.54) SLC18A3ALDH1A1LMNABLMSMN1; SMN2
SCHEMBL4686478 0.83 CARM1 (0.47) SLC18A3OPRM1OPRD1OPRK1ALDH1A1
SCHEMBL18890807 0.82 LSS (0.52) OPRM1LMNACARM1PRMT6TSHR
SCHEMBL5722096 0.81 OPRM1 (0.61) OPRM1OPRD1OPRK1G6PC1HSD17B10
SCHEMBL12126132 0.79 OPRM1 (0.54) OPRM1OPRD1OPRK1TSHRHSD17B10
SCHEMBL10039132 0.79 OPRM1 (0.54) SLC18A3OPRM1OPRD1OPRK1ALDH1A1
SCHEMBL17346290 0.78 OPRM1 (0.43) SLC18A3OPRM1OPRD1OPRK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718643-B2 Multimodal anion exchange matrices CYTIVA BIOPROCESS R&D AB (SE) 2023-08-08 US disclosed
US-11718643-B2 Multimodal anion exchange matrices CYTIVA BIOPROCESS R&D AB (SE) 2023-08-08 US disclosed
US-10815269-B2 Multimodal anion exchange matrices GE HEALTHCARE BIOPROCESS R&D AB (SE) 2020-10-27 US disclosed
US-20190023735-A1 Multimodal Anion Exchange Matrices GE HEALTHCARE BIOPROCESS R&D AB (SE) 2019-01-24 US disclosed
CN-102659718-B Prepare the method for cyclopropyl-amide derivatives JANSSEN PHARMACEUTICA N. V. (BE) 2015-11-25 CN disclosed
US-20150299248-A1 Multimodal Anion Exchange Matrices GE Healtchare Bio-Sciences AB (SE) 2015-10-22 US disclosed
US-20150299248-A1 Multimodal Anion Exchange Matrices GE Healtchare Bio-Sciences AB (SE) 2015-10-22 US disclosed
US-20120283433-A1 NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES MANI NEELAKANDHA S (US) 2012-11-08 US disclosed
US-20120283433-A1 NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES MANI NEELAKANDHA S (US) 2012-11-08 US disclosed
US-20120283433-A1 NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES MANI NEELAKANDHA S (US) 2012-11-08 US disclosed
US-7728129-B2 Processes for the preparation of piperazinyl and diazapanyl benzamide derivatives JANSSEN PHARMACEUTICA NV (BE) 2010-06-01 US disclosed
EP-1951699-A2 PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-06 EP disclosed
US-20070197508-A1 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-23 US disclosed
US-20070197508-A1 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-23 US disclosed
US-20070197508-A1 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-23 US disclosed
US-20070129351-A1 NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-07 US disclosed
US-20070129351-A1 NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-07 US disclosed
US-20070129351-A1 NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-07 US disclosed
WO-2007053386-A2 PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-10 WO disclosed
WO-2007053386-A2 PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815269-B2 Multimodal anion exchange matrices H1-3, H1-4, IGF2R SLC18A3 276/4885OPRM1 55/4885OPRD1 428/4885
US-20070197508-A1 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES HRH2, HRH4, HRH1 SLC18A3 1211/4885OPRM1 1444/4885OPRD1 1034/4885
US-11718643-B2 Multimodal anion exchange matrices H1-3, H1-4, IGF2R SLC18A3 276/4885OPRM1 55/4885OPRD1 428/4885
US-20150299248-A1 Multimodal Anion Exchange Matrices H1-3, H1-4, IGF2R SLC18A3 276/4885OPRM1 55/4885OPRD1 428/4885
US-20190023735-A1 Multimodal Anion Exchange Matrices H1-3, H1-4, IGF2R SLC18A3 276/4885OPRM1 55/4885OPRD1 428/4885
US-20070129351-A1 NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES HRH4, HRH2, HRH1 SLC18A3 291/4885OPRM1 118/4885OPRD1 116/4885
US-20120283433-A1 NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES HRH4, HRH2, HRH1 SLC18A3 291/4885OPRM1 118/4885OPRD1 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.